News briefing: Catalent, Merck KGaA make big investments in manufacturing ops; J&J teams with Datavant on data sharing projects
We’re continuing to see big investments in the global biopharma manufacturing infrastructure.
Wednesday morning Catalent put out the word that it is investing $130 million in its late-stage ops at its gene therapy facility in Harmans, MD. The contract manufacturer has been sinking a significant amount of money into gene therapy as that field continues to boom.
Merck KGaA preceded that announcement with the news that the German biopharma player is triggering a €59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, WI. That move will add 50 new jobs as they ramp up work on the oncology pipeline with new tech that allows continuous manufacturing of ADCs.
“ADCs have posted incredible growth over the last decade, and regulatory agencies’ approvals in recent years demonstrate their promise as a targeted therapy,” said Andrew Bulpin, head of process solutions at the company’s life science business sector.
Jazz hands over $10M to launch a new cancer discovery pact, with $210M up for grabs
Redx is picking up $10 million in cash after inking a new discovery and development pact with Jazz Pharmaceuticals.
The UK biotech will be responsible for exploring two cancer targets on the Ras/Raf/MAP kinase (MAPK) pathway. And there’s another $10 million up for grabs if Jazz wants to push ahead into year 2, with $200 million in milestones at stake.
This new alliance comes just a month after AstraZeneca provided a $17 million lifeline to Redx, which has been in and out of hot water over the years. Right now, things are looking up.
J&J signs up for a 2-way collaboration with Vivek Ramaswamy’s Datavant
Vivek Ramaswamy’s Datavant and J&J have linked up on some data sharing initiatives.
In this new pact, the pharma giant is picking up rights to use Datavant’s tech to “integrate disparate data sets to create rich, longitudinal real-world and clinical datasets to better understand the holistic patient journey, thereby enhancing the design and execution of Janssen’s clinical development programs for patients.”
In return, J&J is offering feedback to Datavant on the products and services it’s providing the industry.
Travis May, Datavant CEO, noted: “The ability to safely connect data from across the healthcare ecosystem to understand the safety and efficacy of, and access to drugs creates the opportunity to greatly improve patient outcomes, and we look forward to building our collaboration.”